Innate Pharma (IPHA) Depreciation & Amortization (IS) (2020 - 2025)

Innate Pharma (IPHA) has 6 years of Depreciation & Amortization (IS) data on file, last reported at $1.6 million in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (IS) fell 24.39% year-over-year to $1.6 million; the trailing twelve-month figure through Dec 2025 stood at $55.5 million (down 6.16% YoY), and the FY2025 full-year result was $1.6 million, down 24.39% from the prior year.
• Depreciation & Amortization (IS) for Q4 2025 stood at $1.6 million, down from $2.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (IS) topped out at $46.3 million in Q4 2022 and bottomed at $1.6 million in Q4 2025.
• The 5-year median for Depreciation & Amortization (IS) is $5.3 million (2021), against an average of $12.2 million.
• The widest annual swing landed in 2021, when Depreciation & Amortization (IS) slumped 92.24%; it then soared 781.08% in 2022.
• A 5-year view of Depreciation & Amortization (IS) shows it stood at $5.3 million in 2021, then jumped by 781.08% to $46.3 million in 2022, then plunged by 88.18% to $5.5 million in 2023, then sank by 61.1% to $2.1 million in 2024, then declined by 24.39% to $1.6 million in 2025.
• The last three Depreciation & Amortization (IS) figures came in at $1.6 million (Q4 2025), $2.1 million (Q4 2024), and $5.5 million (Q4 2023), per Business Quant data.

Peer Comparison